2018
Variable impact of prior cancer history on the survival of lung cancer patients
Monsalve AF, Hoag JR, Resio BJ, Chiu AS, Brown LB, Detterbeck FC, Blasberg JD, Boffa DJ. Variable impact of prior cancer history on the survival of lung cancer patients. Lung Cancer 2018, 127: 130-137. PMID: 30642541, DOI: 10.1016/j.lungcan.2018.11.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPrior cancer historyNational Cancer DatabaseCancer historyOverall survivalNSCLC patientsMultivariable Cox proportional hazards regression modelsTreatment approachesCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesNSCLC patient survivalCell lung cancerHazards regression modelsLung cancer patientsPrior cancerPrior malignancyNSCLC survivalPatient survivalCancer patientsLung cancerCancer DatabasePatient's potentialPrior historyPatients
2017
Fate of Pneumonectomy Patients Variably Captured by Non-Small Cell Lung Cancer Staging System
Dhanasopon AP, Salazar MC, Hoag JR, Rosen JE, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Fate of Pneumonectomy Patients Variably Captured by Non-Small Cell Lung Cancer Staging System. The Annals Of Thoracic Surgery 2017, 104: 1829-1836. PMID: 29074151, DOI: 10.1016/j.athoracsur.2017.06.073.Peer-Reviewed Original ResearchConceptsLung cancer staging systemCancer (AJCC) staging systemPneumonectomy patientsLung cancerMortality riskStage IStaging systemLobectomy patientsCox modelNon-small cell lung cancerMultivariable Cox modelNational Cancer DatabaseTreatment-naive patientsOverall survival curvesCell lung cancerLung cancer patientsBenefits of treatmentHigher mortality riskStage-specific survivalRight pneumonectomyLeft pneumonectomyCancer patientsCancer DatabaseInclusion criteriaPneumonectomy
2015
What is quality, and can we define it in lung cancer?—the case for quality improvement
Farjah F, Detterbeck FC. What is quality, and can we define it in lung cancer?—the case for quality improvement. Translational Lung Cancer Research 2015, 4: 365-72. PMID: 26380177, PMCID: PMC4549465, DOI: 10.3978/j.issn.2218-6751.2015.07.12.Peer-Reviewed Original Research
2011
Impact of Hospital Volume of Thoracoscopic Lobectomy on Primary Lung Cancer Outcomes
Park HS, Detterbeck FC, Boffa DJ, Kim AW. Impact of Hospital Volume of Thoracoscopic Lobectomy on Primary Lung Cancer Outcomes. The Annals Of Thoracic Surgery 2011, 93: 372-379. PMID: 21945225, DOI: 10.1016/j.athoracsur.2011.06.054.Peer-Reviewed Original ResearchConceptsPrimary lung cancer patientsLung cancer patientsShorter LOSMultivariable analysisMedian LOSHospital volumeIndependent predictorsPulmonary lobectomyOpen lobectomyCancer patientsVAT volumeUtilization Project Nationwide Inpatient Sample databaseVideo-assisted thoracoscopic surgery lobectomyHospital operative volumeShorter median LOSLung cancer outcomesPrimary lung cancerHigher hospital volumeShort-term outcomesThoracoscopic surgery lobectomyDiseases procedure codesTotal complicationsHospital lengthHospital morbidityVATS patients
2010
Should the 7th Edition of the Lung Cancer Stage Classification System Change Treatment Algorithms in Non-small Cell Lung Cancer?
Boffa DJ, Detterbeck FC, Smith EJ, Rami-Porta R, Crowley J, Zelterman D, Tanoue L, Kim AW, Goldstraw P. Should the 7th Edition of the Lung Cancer Stage Classification System Change Treatment Algorithms in Non-small Cell Lung Cancer? Journal Of Thoracic Oncology 2010, 5: 1779-1783. PMID: 20975377, DOI: 10.1097/jto.0b013e3181ee80c7.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseCancer DatabaseLung cancer databaseOverall prognosisPatient managementStage shiftNon-small cell lung cancer patientsNon-small cell lung cancerCell lung cancer patientsLung cancer staging systemDownstaging of tumorsLung cancer cliniciansCancer (AJCC) staging systemCell lung cancerLung cancer patientsEdition of TNMCancer SymposiumCancer cliniciansTreatment algorithmStaging systemCancer patientsLung cancerSpecific treatmentTreatment approachesTreatment changesHigh expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2009
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL. High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma. Clinical Cancer Research 2009, 15: 4157-4164. PMID: 19509151, DOI: 10.1158/1078-0432.ccr-09-0099.Peer-Reviewed Original ResearchConceptsLung cancer patientsMTOR expressionCancer patientsMammalian targetEarly-stage lung adenocarcinomaHigh mTOR expressionIndependent lower riskMedian overall survivalStage IA patientsProtein expressionSubgroup of patientsLung adenocarcinoma patientsStage lung adenocarcinomaMTOR protein expressionRole of mTOROverall survivalPathologic characteristicsPatient survivalValidation cohortAdenocarcinoma groupAdenocarcinoma patientsPrognostic stratificationLung cancerTraining cohortFavorable outcome
2005
Chromosomal abnormalities in bronchial epithelium from smokers, nonsmokers, and lung cancer patients
Slebos RJ, Livanos E, Yim HW, Randell SH, Parsons AM, Detterbeck FC, Rivera MP, Taylor JA. Chromosomal abnormalities in bronchial epithelium from smokers, nonsmokers, and lung cancer patients. Cancer Genetics 2005, 159: 137-142. PMID: 15899385, DOI: 10.1016/j.cancergencyto.2004.10.008.Peer-Reviewed Original ResearchConceptsLung cancer patientsCancer patientsNon-lung cancer patientsAbnormal metaphasesChromosomal abnormalitiesHistory of smokingTobacco smoke exposureBronchial epithelial cell culturesHBE cell culturesCell culturesHuman bronchial epithelial cell culturesTobacco smokingSmoke exposureLung cancerEarly treatmentBronchial epitheliumCancer riskIdentification of individualsEpithelial cell culturesPatientsNonsmokersUseful markerGreater riskSmokersObserved abnormalities